Fjoralba Kristo

ORCID: 0000-0002-8045-9756
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Aortic aneurysm repair treatments
  • CNS Lymphoma Diagnosis and Treatment
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Lymphoblastic Leukemia research
  • Cancer-related molecular mechanisms research
  • Cholesterol and Lipid Metabolism
  • Economic and Financial Impacts of Cancer
  • MicroRNA in disease regulation
  • Aortic Disease and Treatment Approaches
  • Atherosclerosis and Cardiovascular Diseases
  • Infectious Aortic and Vascular Conditions
  • Cancer Genomics and Diagnostics
  • Medical Imaging Techniques and Applications
  • Cardiac, Anesthesia and Surgical Outcomes
  • Cancer Treatment and Pharmacology
  • Inflammatory Biomarkers in Disease Prognosis
  • Chronic Myeloid Leukemia Treatments
  • Histone Deacetylase Inhibitors Research
  • Statistical Methods in Clinical Trials
  • Medication Adherence and Compliance
  • Cancer, Lipids, and Metabolism
  • Colorectal Cancer Treatments and Studies

Takeda (United States)
2021-2025

Millennium Engineering and Integration (United States)
2021-2022

Massachusetts General Hospital
2007-2015

Center for Cancer Research
2015

University of Kentucky
2009-2010

Harvard University
2007-2009

Proper coordination of cholesterol biosynthesis and trafficking is essential to human health. The sterol regulatory element-binding proteins (SREBPs) are key transcription regulators genes involved in uptake. We show here that microRNAs (miR-33a/b) embedded within introns the SREBP target adenosine triphosphate-binding cassette transporter A1 (ABCA1), an important regulator high-density lipoprotein (HDL) synthesis reverse transport, for posttranscriptional repression. Antisense inhibition...

10.1126/science.1189123 article EN Science 2010-05-14

V. Rottiers1,2, S.H. Najafi-Shoushtari1,2, F. Kristo3, S. Gurumurthy1, L. Zhong1, Y. Li4, D.E. Cohen4, R.E. Gerszten3,5, N. Bardeesy1,6, R. Mostoslavsky1,6 and A.M. Näär1,2 Massachusetts General Hospital Cancer Center, Charlestown, 02129 Department of Cell Biology, Harvard Medical School, Boston, 02115 Center for Immunology Inflammatory Diseases, Hospital, Medicine, Division Gastroenterology, Brigham Women's Cardiovascular Research Correspondence: naar{at}helix.mgh.harvard.edu

10.1101/sqb.2011.76.011049 article EN Cold Spring Harbor Symposia on Quantitative Biology 2011-01-01

Background— Vascular disease can manifest as stenotic plaques or ectatic aneurysms, although the mechanisms culminating in these divergent manifestations remain poorly understood. T-helper type 1 cytokines, including interferon-γ and CXCL10, have been strongly implicated atherosclerotic plaque development. Methods Results— Here, we specifically examined their role formation of abdominal aortic aneurysms angiotensin II–induced murine model. Unexpectedly, found increased suprarenal diameters,...

10.1161/circulationaha.108.785949 article EN Circulation 2009-01-13

Abstract Leukotriene B4 is a proinflammatory lipid mediator generated by the enzymes 5-lipoxygenase and leukotriene A4 hydrolase. signals primarily through its high-affinity G protein-coupled receptor, BLT1, which highly expressed on specific leukocyte subsets. Recent genetic studies in humans as well knockout mice have implicated synthesis pathway several vascular pathologies. In this study, we tested hypothesis that BLT1 necessary for abdominal aortic aneurysm (AAA) formation, major...

10.4049/jimmunol.179.1.691 article EN The Journal of Immunology 2007-07-01

Aim: Forty percent of patients with higher-risk myelodysplastic syndromes (HR-MDS) transform to acute myeloid leukemia (AML). Materials & methods: This retrospective study assessed the impact HR-MDS transformation AML on OS in a 6-month landmark analysis and results were validated using time-varying analysis. Results: The rate was 26.9% at 1 year. Patients who transformed had higher risk death than did not (HR: 1.82; p: 0.0072) year 2.85; p < 0.0001). treated azacitidine decitabine...

10.2217/fon-2022-0334 article EN cc-by-nc-nd Future Oncology 2022-11-01

Transformation of higher-risk myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) may be associated with increased healthcare resource utilization (HCRU) and costs. To describe this economic impact, HCRU costs were compared between US patients who experienced transformation AML those did not. Using the Optum administrative claims data, retrospective matched cohort study identified (≥ 18 years old) MDS initiated first-line therapy January 1, 2008, June 30, 2019. Patients whose...

10.1007/s12325-022-02370-4 article EN cc-by-nc Advances in Therapy 2022-11-24

Proper coordination of cholesterol/lipid biosynthesis, trafficking, and degradation is essential to human health. The sterol regulatory element–binding proteins (SREBPs) are key transcription regulators genes involved in biosynthesis uptake. However, it has remained unclear how SREBP-dependent gene processes integrated with other cellular pathways controlling metabolism energy homeostasis. We will present studies revealing novel networks involving SREBPs, sirtuins microRNAs that modulate...

10.1096/fasebj.25.1_supplement.193.1 article EN The FASEB Journal 2011-04-01

353 Background: Social determinants of health (SDoH) are non-medical factors, such as income, education, employment, and area residence that can influence outcomes. Research shows SDoH impact people’s health, well-being, quality life (QoL) and, for patients with cancer, treatment Electronic Patient Reported Outcomes (ePROs) integration into routine oncology practice improves patient time on therapy, survival, resource utilization. This study explores the use an ePRO platform gathering care...

10.1200/op.2023.19.11_suppl.353 article EN JCO Oncology Practice 2023-10-26

349 Background: Patients with AML and poor-risk cytogenetic abnormalities often have suboptimal treatment response poor long-term survival, Electronic Patient Reported Outcomes (ePROs) integration into routine oncology practice been shown to improve patient time on therapy, resource utilization. This study explores the use of an ePRO platform explore differences in experience compliance patients other-risk cytogenetics. Methods: Adult undergoing were enrolled Carevive remote symptom...

10.1200/op.2023.19.11_suppl.349 article EN JCO Oncology Practice 2023-10-26

354 Background: Social determinants of health (SDoH) are non-medical factors, such as income, education, employment, and area residence, that can influence outcomes. Research shows SDoH impact people’s health, well-being, quality life (QoL) and, for patients with cancer, treatment Electronic Patient Reported Outcomes (ePROs) integration into routine oncology practice improves patient time on therapy, survival, resource utilization. This study explores the use an ePRO platform gathering...

10.1200/op.2023.19.11_suppl.354 article EN JCO Oncology Practice 2023-10-26
Coming Soon ...